透景生命拟3.28亿收购康录生物82%股份 加码分子病理领域布局

Group 1 - The core point of the article is that TuoJing Life plans to acquire a controlling stake of 82% in Wuhan Kanglu Biological by first purchasing 72.86% of its shares, with a total transaction amount of 328 million yuan [1][2] - The acquisition is structured in three phases, with the final phase expected to be completed by 2027, contingent upon meeting certain preconditions [1][2] - Wuhan Kanglu Biological specializes in the FISH and PCR molecular diagnostic fields, having received multiple NMPA approvals for its medical devices, indicating a strong regulatory standing [2] Group 2 - In the first five months of 2025, Wuhan Kanglu Biological reported a revenue of 36.54 million yuan and a net profit of 6.86 million yuan, showcasing its financial performance [2] - The valuation of Wuhan Kanglu Biological reflects an increase of 278 million yuan, with a growth rate of 226.53%, attributed to its focus on major diseases and strong marketing channels [2] - The sellers have committed to achieving a total net profit of no less than 91.5 million yuan from 2025 to 2027, with R&D expenses being at least 10% of annual revenue [2][3] Group 3 - The funding for the acquisition will come from the company's own funds and bank loans, with payments made in installments based on the transaction progress, ensuring minimal impact on cash flow [3] - If the performance commitments are met, the acquisition is expected to positively influence the company's operational performance [3]